{"nctId":"NCT00598442","briefTitle":"Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis","startDateStruct":{"date":"2007-11"},"conditions":["Chronic Renal Failure","Chronic Kidney Disease","Anemia"],"count":493,"armGroups":[{"label":"Peginesatide 0.025 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: peginesatide"]},{"label":"Peginesatide 0.04 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: peginesatide"]},{"label":"Darbepoetin alfa","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Darbepoetin alfa"]}],"interventions":[{"name":"peginesatide","otherNames":["Omontys","Hematide","AF37702 Injection"]},{"name":"peginesatide","otherNames":["Omontys","Hematide","AF37702 Injection"]},{"name":"Darbepoetin alfa","otherNames":["Aranesp"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Chronic renal failure with an estimated glomerular filtration rate \\< 60 milliliters per minute per 1.73 m\\^2 and not expected to begin dialysis for at least 12 weeks.\n2. Two consecutive hemoglobin values ≥ 8.0 g/dL and \\< 11.0 g/dL within 4 weeks prior to randomization.\n\nExclusion Criteria:\n\n1. Females who are pregnant or breast-feeding.\n2. Treatment with an ESA in the 12 weeks prior to randomization.\n3. Known intolerance to any ESA, parenteral iron supplementation, or pegylated molecule.\n4. Prior chronic hemodialysis or chronic peritoneal dialysis treatment.\n5. Known bleeding or coagulation disorder.\n6. Known hematologic disease or cause of anemia other than renal disease.\n7. Poorly controlled hypertension.\n8. Evidence of active malignancy within one year prior to randomization\n9. A scheduled kidney transplant.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in Hemoglobin Between Baseline and the Evaluation Period","description":"The baseline hemoglobin value is defined as the mean of three hemoglobin values: the two most recent hemoglobin values taken prior to the day of randomization and the value obtained on the day of randomization. The mean hemoglobin during the Evaluation Period for each participant is calculated as the mean of the available hemoglobin values during Study Weeks 25 through 36.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.02","spread":"0.626"},{"groupId":"OG001","value":"10.03","spread":"0.618"},{"groupId":"OG002","value":"10.03","spread":"0.654"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.55","spread":"0.741"},{"groupId":"OG001","value":"11.71","spread":"0.855"},{"groupId":"OG002","value":"11.40","spread":"0.728"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.898"},{"groupId":"OG001","value":"1.68","spread":"0.962"},{"groupId":"OG002","value":"1.35","spread":"1.004"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Who Received Red Blood Cell (RBC) Transfusions During the Correction and Evaluation Periods","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.114","spread":null},{"groupId":"OG001","value":"0.104","spread":null},{"groupId":"OG002","value":"0.049","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving Hemoglobin Response During the Correction and Evaluation Periods","description":"A hemoglobin response is defined as a hemoglobin increase of ≥ 1.0 gram per deciliter (g/dL) above baseline and a hemoglobin ≥ 11.0 g/dL without RBC transfusion during the previous 8 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.910","spread":null},{"groupId":"OG001","value":"0.933","spread":null},{"groupId":"OG002","value":"0.951","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":86,"n":167},"commonTop":["Oedema peripheral","Hypertension","Nausea","Diarrhoea","Hyperkalaemia"]}}}